Tyler Jacks

List of Publications by Citations

241 papers	80,326 citations	115 h-index	252 g-index
252 ext. papers	88,698 ext. citations	23.8 avg, IF	7.48 L-index

#	Paper	IF	Citations
241	MicroRNA expression profiles classify human cancers. *Nature*, **2005**, 435, 834-8	50.4	7870
240	Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. *Nature*, **2009**, 458, 223-7	50.4	3230
239	A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. *Cell*, **1992**, 71, 587-97	56.2	2767
238	p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. *Cell*, **1993**, 74, 957-67	56.2	2622
237	p53 is required for radiation-induced apoptosis in mouse thymocytes. *Nature*, **1993**, 362, 847-9	50.4	2565
236	Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. *Nature*, **1996**, 379, 88-91	50.4	2026
235	Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell*, **2003**, 4, 437-50	24.3	1772
234	Identification of bronchioalveolar stem cells in normal lung and lung cancer. *Cell*, **2005**, 121, 823-35	56.2	1746
233	Tumor spectrum analysis in p53-mutant mice. *Current Biology*, **1994**, 4, 1-7	6.3	1731
232	A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. *Cell*, **2010**, 142, 409-19	56.2	1648
231	Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. *Nature*, **2009**, 462, 108-12	50.4	1614
230	Effects of an Rb mutation in the mouse. *Nature*, **1992**, 359, 295-300	50.4	1599
229	Sunburn and p53 in the onset of skin cancer. *Nature*, **1994**, 372, 773-6	50.4	1520
228	Restoration of p53 function leads to tumour regression in vivo. *Nature*, **2007**, 445, 661-5	50.4	1388
227	Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. *Genes and Development*, **2001**, 15, 3243-8	12.6	1376
226	Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. *Cell*, **2008**, 132, 875-86	56.2	1332
225	Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. *Cell*, **1992**, 70, 923-35	56.2	1242

224	Impaired microRNA processing enhances cellular transformation and tumorigenesis. *Nature Genetics*, **2007**, 39, 673-7	36.3	1235
223	Radiation-induced cell cycle arrest compromised by p21 deficiency. *Nature*, **1995**, 377, 552-7	50.4	1119
222	Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. *Cell*, **2004**, 119, 847-60	56.2	957
221	Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. *Nature*, **2001**, 410, 1111	56.4	932
220	p53-dependent apoptosis suppresses tumor growth and progression in vivo. *Cell*, **1994**, 78, 703-11	56.2	801
219	Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. *Nature*, **1988**, 331, 280-3	50.4	775
218	MicroRNAs and cancer: short RNAs go a long way. *Cell*, **2009**, 136, 586-91	56.2	762
217	Suppression of non-small cell lung tumor development by the let-7 microRNA family. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 3903-8	11.5	723
216	p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. *Nature*, **2002**, 416, 560-4	50.4	718
215	Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. *Nature Biotechnology*, **2014**, 32, 551-3	44.5	694
214	Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. *Nature Medicine*, **2005**, 11, 63-70	50.5	691
213	Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. *Nature Genetics*, **1994**, 7, 353-61	36.3	664
212	Tumor induction and tissue atrophy in mice lacking E2F-1. *Cell*, **1996**, 85, 537-48	56.2	620
211	Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. *Cancer Cell*, **2004**, 5, 375-87	24.3	612
210	p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. *Nature*, **1994**, 371, 72-4	50.4	587
209	STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. *Oncogene*, **2001**, 20, 5054-8	9.2	569
208	Role for the p53 homologue p73 in E2F-1-induced apoptosis. *Nature*, **2000**, 407, 645-8	50.4	546
207	Signals for ribosomal frameshifting in the Rous sarcoma virus gag-pol region. *Cell*, **1988**, 55, 447-58	56.2	546

206	Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. *Nature Protocols*, **2009**, 4, 1064-72	18.8	532
205	Cre-lox-regulated conditional RNA interference from transgenes. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 10380-5	11.5	523
204	CRISPR-mediated direct mutation of cancer genes in the mouse liver. *Nature*, **2014**, 514, 380-4	50.4	521
203	A subset of p53-deficient embryos exhibit exencephaly. *Nature Genetics*, **1995**, 10, 175-80	36.3	501
202	NF1 tumor suppressor gene function: narrowing the GAP. *Cell*, **2001**, 104, 593-604	56.2	493
201	Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. *Genes and Development*, **2000**, 14, 3037-50	12.6	487
200	KRAS and YAP1 converge to regulate EMT and tumor survival. *Cell*, **2014**, 158, 171-84	56.2	482
199	Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. *Nature Genetics*, **1996**, 12, 144-8	36.3	474
198	Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer. *Cell Metabolism*, **2016**, 23, 517-28	24.6	463
197	Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. *Nature*, **2003**, 424, 223-8	50.4	461
196	Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. *Cell*, **2009**, 137, 821-34	56.2	454
195	Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. *Nature*, **2002**, 415, 526-30	50.4	447
194	Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. *Nature Genetics*, **2008**, 40, 600-8	36.3	441
193	Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. *Molecular and Cellular Biology*, **1998**, 18, 1055-64	4.8	439
192	Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. *Genes and Development*, **2013**, 27, 1447-61	12.6	433
191	Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. *Nature*, **2009**, 462, 104-7	50.4	431
190	Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. *Cancer Cell*, **2005**, 7, 363-73	24.3	425
189	The differential effects of mutant p53 alleles on advanced murine lung cancer. *Cancer Research*, **2005**, 65, 10280-8	10.1	401

188	Expression of tumour-specific antigens underlies cancer immunoediting. *Nature*, **2012**, 482, 405-9	50.4	391
187	Mouse models of tumor development in neurofibromatosis type 1. *Science*, **1999**, 286, 2172-6	33.3	387
186	An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. *Nature Genetics*, **2005**, 37, 48-55	36.3	361
185	Dicer1 functions as a haploinsufficient tumor suppressor. *Genes and Development*, **2009**, 23, 2700-4	12.6	353
184	Cooperative tumorigenic effects of germline mutations in Rb and p53. *Nature Genetics*, **1994**, 7, 480-4	36.3	348
183	Autophagy is required for glucose homeostasis and lung tumor maintenance. *Cancer Discovery*, **2014**, 4, 914-27	24.4	347
182	The retinoblastoma gene family in differentiation and development. *Oncogene*, **1999**, 18, 7873-82	9.2	344
181	Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. *Molecular Cell*, **1998**, 2, 293-304	17.6	339
180	Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. *Cell*, **2008**, 134, 62-73	56.2	336
179	PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. *Cell*, **2013**, 155, 397-409	56.2	333
178	Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. *Nature Genetics*, **2000**, 26, 109-13	36.3	325
177	Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. *Science*, **2016**, 353, 1161-5	33.3	324
176	Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. *Nature*, **1995**, 377, 695-701	50.4	323
175	LincRNA-p21 activates p21 in cis to promote Polycomb target gene expression and to enforce the G1/S checkpoint. *Molecular Cell*, **2014**, 54, 777-90	17.6	319
174	Suppression of lung adenocarcinoma progression by Nkx2-1. *Nature*, **2011**, 473, 101-4	50.4	312
173	Cancer modeling in the modern era: progress and challenges. *Cell*, **2002**, 108, 135-44	56.2	304
172	Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. *Nature Medicine*, **2017**, 23, 1362-1368	50.5	301
171	Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. *Cancer Research*, **2004**, 64, 2307-16	10.1	291

170	Commensal Microbiota Promote Lung Cancer Development via T Cells. *Cell*, **2019**, 176, 998-1013.e16	56.2	290
169	The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. *Developmental Cell*, **2001**, 1, 63-72	10.2	288
168	Rapid modelling of cooperating genetic events in cancer through somatic genome editing. *Nature*, **2014**, 516, 428-31	50.4	278
167	A mouse model for the learning and memory deficits associated with neurofibromatosis type I. *Nature Genetics*, **1997**, 15, 281-4	36.3	278
166	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. *Nature Medicine*, **2015**, 21, 1163-71	50.5	275
165	MHC-II neoantigens shape tumour immunity and response to immunotherapy. *Nature*, **2019**, 574, 696-70	50.4	272
164	Applications of the CRISPR-Cas9 system in cancer biology. *Nature Reviews Cancer*, **2015**, 15, 387-95	31.3	260
163	Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. *Cancer Cell*, **2009**, 16, 379-89	24.3	257
162	Taking the study of cancer cell survival to a new dimension. *Cell*, **2002**, 111, 923-5	56.2	253
161	PKM2, cancer metabolism, and the road ahead. *EMBO Reports*, **2016**, 17, 1721-1730	6.5	249
160	Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-)mice. *Nature Genetics*, **1998**, 18, 360-4	36.3	248
159	Characterizing deformability and surface friction of cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 7580-5	11.5	243
158	Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. *Immunity*, **2015**, 43, 579-90	32.3	242
157	A spatially and temporally restricted mouse model of soft tissue sarcoma. *Nature Medicine*, **2007**, 13, 992-7	50.5	222
156	Circadian Rhythm Disruption Promotes Lung Tumorigenesis. *Cell Metabolism*, **2016**, 24, 324-31	24.6	219
155	Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. *Journal of Clinical Investigation*, **2004**, 113, 528-38	15.9	218
154	Stage-specific sensitivity to p53 restoration during lung cancer progression. *Nature*, **2010**, 468, 572-5	50.4	208
153	Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. *Molecular Cell*, **2003**, 12, 841-9	17.6	199

152	Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. *Cell*, **2014**, 156, 1298-1311	56.2	191
151	A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. *Nature*, **2017**, 545, 355-359	50.4	190
150	Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. *Journal of Biological Chemistry*, **2002**, 277, 10394-9	5.4	182
149	Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 8773-8	11.5	181
148	Small RNA combination therapy for lung cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E3553-61	11.5	177
147	Cell type-specific effects of Rb deletion in the murine retina. *Genes and Development*, **2004**, 18, 1681-94	12.6	176
146	In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. *Nature Biotechnology*, **2017**, 35, 569-576	44.5	168
145	PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. *Genes and Development*, **2000**, 14, 704-718	12.6	165
144	RhoA-dependent phosphorylation and relocalization of ERM proteins into apical membrane/actin protrusions in fibroblasts. *Molecular Biology of the Cell*, **1998**, 9, 403-19	3.5	163
143	Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. *Cancer Cell*, **2011**, 19, 72-85	24.3	159
142	Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 2948-53	11.5	157
141	Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. *Molecular Cell*, **2013**, 50, 185-99	17.6	150
140	Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. *Genes and Development*, **2010**, 24, 837-52	12.6	147
139	Lung Adenocarcinoma Distally Rewires Hepatic Circadian Homeostasis. *Cell*, **2016**, 165, 896-909	56.2	147
138	Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 20786-91	11.5	144
137	Requirement for Rac1 in a K-ras induced lung cancer in the mouse. *Cancer Research*, **2007**, 67, 8089-94	10.1	140
136	Targeted deletion reveals an essential function for the telomere length regulator Trf1. *Molecular and Cellular Biology*, **2003**, 23, 6533-41	4.8	137
135	Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. *Journal of Experimental Medicine*, **1998**, 187, 1893-902	16.6	131

134	p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells. *Journal of Cell Biology*, **1998**, 141, 503-14	7.3	128
133	A dominant-negative effect drives selection of missense mutations in myeloid malignancies. *Science*, **2019**, 365, 599-604	33.3	127
132	Nf1 and Gmcsf interact in myeloid leukemogenesis. *Molecular Cell*, **2000**, 5, 189-95	17.6	122
131	ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. *Cancer Research*, **2006**, 66, 7473-81	10.1	119
130	Nuclear factor I/B is an oncogene in small cell lung cancer. *Genes and Development*, **2011**, 25, 1470-5	12.6	118
129	Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 14404-9	11.5	118
128	Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. *Cancer Research*, **2006**, 66, 242-7	10.1	116
127	Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E6409-E6417	11.5	111
126	Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. *Blood*, **2011**, 117, 2022-32	2.2	110
125	Mammalian RNAi: a practical guide. *BioTechniques*, **2005**, 39, 215-24	2.5	110
124	Modeling human lung cancer in mice: similarities and shortcomings. *Oncogene*, **1999**, 18, 5318-24	9.2	110
123	Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. *EMBO Journal* , **2004**, 23, 3689-99	13	108
122	p63 and p73 transcriptionally regulate genes involved in DNA repair. *PLoS Genetics*, **2009**, 5, e1000680	6	107
121	Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. *Genes and Development*, **2003**, 17, 449-54	12.6	106
120	Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. *Molecular and Cellular Biology*, **2004**, 24, 8884-94	4.8	106
119	Response and resistance to NF-B inhibitors in mouse models of lung adenocarcinoma. *Cancer Discovery*, **2011**, 1, 236-47	24.4	104
118	Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. *Molecular Cell*, **2011**, 43, 57-71	17.6	102
117	HIF-2alpha deletion promotes Kras-driven lung tumor development. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 14182-7	11.5	102

116	Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. *Genes and Development*, **2007**, 21, 694-707	12.6	101
115	Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli. *Journal of Biological Chemistry*, **1998**, 273, 7757-64	5.4	99
114	Stromal Expression of miR-143/145 Promotes Neoangiogenesis in Lung Cancer Development. *Cancer Discovery*, **2016**, 6, 188-201	24.4	98
113	Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo. *Molecular and Cellular Biology*, **2003**, 23, 9094-103	4.8	95
112	Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer. *Oncogene*, **2004**, 23, 973-80	9.2	93
111	Insights into cancer from transgenic mouse models. *Journal of Pathology*, **1999**, 187, 43-60	9.4	93
110	Tumor suppressor gene mutations in mice. *Annual Review of Genetics*, **1996**, 30, 603-36	14.5	93
109	Perp is a mediator of p53-dependent apoptosis in diverse cell types. *Current Biology*, **2003**, 13, 1985-90	6.3	91
108	Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma. *Genes and Development*, **2016**, 30, 1020-33	12.6	91
107	Involvement of p53 and p21 in cellular defects and tumorigenesis in Atm-/- mice. *Molecular and Cellular Biology*, **1998**, 18, 4385-90	4.8	90
106	Survival of pancreatic cancer cells lacking KRAS function. *Nature Communications*, **2017**, 8, 1090	17.4	88
105	The Rb tumor suppressor is required for stress erythropoiesis. *EMBO Journal*, **2004**, 23, 4319-29	13	84
104	Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation. *Molecular and Cellular Biology*, **2011**, 31, 1565-76	4.8	82
103	Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 13008-13	11.5	81
102	An induced Ets repressor complex regulates growth arrest during terminal macrophage differentiation. *Cell*, **2002**, 109, 169-80	56.2	80
101	Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E5625-E5634	11.5	78
100	Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q-syndrome. *Blood*, **2011**, 118, 4666-73	2.2	76
99	RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. *Nucleic Acids Research*, **2004**, 32, 25-34	20.1	76

98	Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. *Cancer Cell*, **2020**, 38, 229-246.e13	24.3	76
97	In Vitro and In Vivo Effects of a Farnesyltransferase Inhibitor onNf1-Deficient Hematopoietic Cells. *Blood*, **1999**, 94, 2469-2476	2.2	74
96	Notum produced by Paneth cells attenuates regeneration of aged intestinal epithelium. *Nature*, **2019**, 571, 398-402	50.4	72
95	p130 is dispensable in peripheral T lymphocytes: evidence for functional compensation by p107 and pRB. *Molecular and Cellular Biology*, **1998**, 18, 206-20	4.8	72
94	The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. *Journal of Thoracic Oncology*, **2015**, 10, 553-64	8.9	71
93	A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. *Cell Reports*, **2013**, 5, 868-77	10.6	71
92	Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. *Genes and Development*, **2015**, 29, 1850-62	12.6	68
91	Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis. *Cancer Research*, **2011**, 71, 4040-7	10.1	67
90	ARF is not required for apoptosis in Rb mutant mouse embryos. *Current Biology*, **2002**, 12, 159-63	6.3	66
89	Technologically advanced cancer modeling in mice. *Current Opinion in Genetics and Development*, **2002**, 12, 105-10	4.9	66
88	Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification. *EMBO Journal*, **2007**, 26, 784-94	13	64
87	Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. *Cancer Research*, **2006**, 66, 2527-31	10.1	64
86	Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. *Nature Biotechnology*, **2010**, 28, 71-8	44.5	62
85	The related retinoblastoma (pRb) and p130 proteins cooperate to regulate homeostasis in the intestinal epithelium. *Journal of Biological Chemistry*, **2006**, 281, 638-47	5.4	61
84	Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. *Current Opinion in Immunology*, **2013**, 25, 192-9	7.8	60
83	A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. *Nature Genetics*, **2006**, 38, 926-30	36.3	59
82	Epigenomic State Transitions Characterize Tumor Progression in Mouse Lung Adenocarcinoma. *Cancer Cell*, **2020**, 38, 212-228.e13	24.3	57
81	Proliferation and tumorigenesis of a murine sarcoma cell line in the absence of DICER1. *Cancer Cell*, **2012**, 21, 848-55	24.3	55

80	Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. *Cancer Research*, **2005**, 65, 8166-73	10.1	52
79	Differential Tks5 isoform expression contributes to metastatic invasion of lung adenocarcinoma. *Genes and Development*, **2013**, 27, 1557-67	12.6	51
78	Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 10184-9	11.5	50
77	A big step in the study of small cell lung cancer. *Cancer Cell*, **2003**, 4, 163-6	24.3	50
76	Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. *Genes and Development*, **2013**, 27, 197-210	12.6	47
75	Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. *Cancer Discovery*, **2013**, 3, 993-1001	24.4	47
74	Imaging primary lung cancers in mice to study radiation biology. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, 973-7	4	47
73	Rb and N-ras function together to control differentiation in the mouse. *Molecular and Cellular Biology*, **2003**, 23, 5256-68	4.8	46
72	Myeloid Malignancies Induced by Alkylating Agents in Nf1 Mice. *Blood*, **1999**, 93, 3617-3623	2.2	46
71	A versatile reporter system for CRISPR-mediated chromosomal rearrangements. *Genome Biology*, **2015**, 16, 111	18.3	45
70	Colonoscopy-based colorectal cancer modeling in mice with CRISPR-Cas9 genome editing and organoid transplantation. *Nature Protocols*, **2018**, 13, 217-234	18.8	41
69	Identification of DHODH as a therapeutic target in small cell lung cancer. *Science Translational Medicine*, **2019**, 11,	17.5	40
68	Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents. *Oncogene*, **2004**, 23, 4107-20	9.2	40
67	Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. *Cancer Research*, **2008**, 68, 9459-68	10.1	38
66	Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. *Genes Chromosomes and Cancer*, **2006**, 45, 338-48	5	38
65	Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. *Cancer Research*, **2007**, 67, 4648-56	10.1	38
64	Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene. *Oncogene*, **2002**, 21, 5990-7	9.2	36
63	Characterization of Pheochromocytomas in a Mouse Strain with a Targeted Disruptive Mutation of the Neurofibromatosis Gene Nf1. *Endocrine Pathology*, **1995**, 6, 323-335	4.2	36

62	Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers. *Nature Communications*, **2016**, 7, 12685	17.4	35
61	ARF mutation accelerates pituitary tumor development in Rb+/- mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 16865-70	11.5	35
60	A Modular Assembly Platform for Rapid Generation of DNA Constructs. *Scientific Reports*, **2016**, 6, 16836	4.9	34
59	Generation of normal lymphocyte populations by Rb-deficient embryonic stem cells. *Current Biology*, **1993**, 3, 405-13	6.3	34
58	Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. *Cell*, **2020**, 181, 832-847.e18	56.2	34
57	SnapShot: Lung cancer models. *Cell*, **2012**, 149, 246-246.e1	56.2	29
56	Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction. *Cancer Discovery*, **2013**, 3, 908-21	24.4	29
55	Lessons from the p53 mutant mouse. *Journal of Cancer Research and Clinical Oncology*, **1996**, 122, 319-27	4.9	29
54	Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 17460-17469	11.5	28
53	Thinking beyond the tumor cell: Nf1 haploinsufficiency in the tumor environment. *Cancer Cell*, **2002**, 1, 408-10	24.3	28
52	Lack of p53 Ser389 phosphorylation predisposes mice to develop 2-acetylaminofluorene-induced bladder tumors but not ionizing radiation-induced lymphomas. *Cancer Research*, **2005**, 65, 3610-6	10.1	28
51	CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 513-521	11.5	27
50	Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma. *ELife*, **2020**, 9,	8.9	26
49	Tumor suppression by a severely truncated species of retinoblastoma protein. *Molecular and Cellular Biology*, **2002**, 22, 3103-10	4.8	25
48	Genetically engineered mouse models of astrocytoma: GEMs in the rough?. *Seminars in Cancer Biology*, **2001**, 11, 177-91	12.7	24
47	IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development. *Cell Reports*, **2019**, 29, 2998-3008.e8	10.6	24
46	Mechanisms of carcinogenesis and the mutant mouse. *Current Opinion in Genetics and Development*, **1996**, 6, 65-70	4.9	23
45	Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling. *Science Translational Medicine*, **2020**, 12,	17.5	22

44	Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. *Cancer Research*, **2018**, 78, 985-1002	10.1	21
43	Progressive genomic instability in the FVB/Kras(LA2) mouse model of lung cancer. *Molecular Cancer Research*, **2011**, 9, 1339-45	6.6	20
42	A mouse plasma peptide atlas as a resource for disease proteomics. *Genome Biology*, **2008**, 9, R93	18.3	20
41	Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): a case report and laboratory investigation. *Journal of Pediatric Hematology/Oncology*, **2003**, 25, 644-8	1.2	20
40	Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	20
39	NF-kappaB fans the flames of lung carcinogenesis. *Cancer Prevention Research*, **2010**, 3, 403-5	3.2	19
38	The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. *Cancer Cell*, **2021**, 39, 1342-1360.e14	24.3	18
37	Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma. *Cancer & Metabolism*, **2018**, 6, 6	5.4	17
36	Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. *Oncogene*, **2004**, 23, 7644-50	9.2	17
35	Future of early detection of lung cancer: the role of mouse models. *Clinical Cancer Research*, **2005**, 11, 4999s-5003s	12.9	17
34	Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1 CD8 T□cells in tumor-draining lymph nodes. *Immunity*, **2021**, 54, 2338-2353.e6	32.3	17
33	Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1. *Nature Cancer*, **2020**, 1, 589-602	15.4	16
32	Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer. *Nano Letters*, **2018**, 18, 2195-2208	11.5	16
31	Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. *Nature Genetics*, **1997**, 16, 336-7	36.3	15
30	Tumor suppressor mutations in mice: the next generation. *Current Opinion in Genetics and Development*, **1998**, 8, 304-10	4.9	14
29	Recombinase-based conditional and reversible gene regulation via XTR alleles. *Nature Communications*, **2015**, 6, 8783	17.4	13
28	Defective proliferative responses in B lymphocytes and thymocytes that lack neurofibromin. *Molecular Immunology*, **2002**, 38, 701-8	4.3	13
27	BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency. *Cancer Research*, **2020**, 80, 3841-3854	10.1	13

26	Antigen dominance hierarchies shape TCF1 progenitor CD8 T cell phenotypes in tumors. *Cell*, **2021**, 184, 4996-5014.e26	56.2	13
25	Inducible de novo expression of neoantigens in tumor cells and mice. *Nature Biotechnology*, **2021**, 39, 64-73	44.5	12
24	Dicer loss and recovery induce an oncogenic switch driven by transcriptional activation of the oncofetal Imp1-3 family. *Genes and Development*, **2017**, 31, 674-687	12.6	11
23	Modulation of tumor induction and progression of oncogenic K-ras-positive tumors in the presence of TGF- b1 haploinsufficiency. *Carcinogenesis*, **2007**, 28, 2589-96	4.6	11
22	Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. *Nature Cancer*, **2021**, 2, 1071-1085	15.4	8
21	Nf1 gene targeting: toward models and mechanisms. *Seminars in Cancer Biology*, **1996**, 7, 291-8	12.7	7
20	Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	7
19	Measuring kinetics and metastatic propensity of CTCs by blood exchange between mice. *Nature Communications*, **2021**, 12, 5680	17.4	7
18	Spatial genomics enables multi-modal study of clonal heterogeneity in tissues.. *Nature*, **2021**,	50.4	6
17	Myeloid Malignancies Induced by Alkylating Agents in Nf1 Mice. *Blood*, **1999**, 93, 3617-3623	2.2	6
16	Neurofibromatosis type 1. *Methods in Molecular Biology*, **2003**, 222, 223-37	1.4	5
15	Live cell tagging tracking and isolation for spatial transcriptomics using photoactivatable cell dyes. *Nature Communications*, **2021**, 12, 4995	17.4	5
14	Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution.. *Cell*, **2022**,	56.2	4
13	Genetic Mouse Models of Cancer **2015**, 145-154.e2		3
12	Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer. *Cancer Discovery*, **2021**,	24.4	3
11	SMARCA4 inactivation promotes lineage-specific transformation and early metastatic features in the lung. *Cancer Discovery*, **2021**,	24.4	3
10	Deciphering the immunopeptidome in vivo reveals new tumour antigens. *Nature*,	50.4	3
9	Spatially-Resolved Live Cell Tagging and Isolation Using Protected Photoactivatable Cell Dyes		1

List of Publications

8	The mutational landscape of EGFR-, MYC-, and Kras- driven genetically-engineered mouse models of lung adenocarcinoma		1
7	Longitudinal single cell profiling of regulatory T cells identifies IL-33 as a driver of tumor immunosuppression		1
6	Basic Mouse Methods for Clinician Researchers: Harnessing the Mouse for Biomedical Research **2017**, 291-312		0
5	A GATA4-regulated secretory program suppresses tumors through recruitment of cytotoxic CD8 T cells.. *Nature Communications*, **2022**, 13, 256	17.4	0
4	Protocol for single-cell ATAC sequencing using combinatorial indexing in mouse lung adenocarcinoma. *STAR Protocols*, **2021**, 2, 100583	1.4	0
3	Genetic Mouse Models of Cancer **2008**, 129-138		
2	Roles of microRNAs in cancer and development322-337		
1	p53 Family Members: p63 and p73 **2005**, 187-198		